Since the first HDAC inhibitor, vorinostat, approved for the treatment of cutaneous T-cell lymphoma in 2006, five HDAC inhibitors have been approved for T-cell lymphoma and solid tumors [5]. This evidence concerns the gene HDAC9 and T-cell non-Hodgkin lymphoma.